EUROAPI Hungary Ltd.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products, Lessors of Real Property, Not Elsewhere Classified, Land Subdividers and Developers, Except Cemeteries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about EUROAPI Hungary Ltd.
Live alerts from global media, monitored by Business Radar
2023-10-10 (pharmaphorum.com)
Sanofi spin-off EuroAPI slumps as revenues falter |
Shares in EuroAPI, the active pharmaceutical ingredients (API) business spun out of Sanofi last year, have fallen sharply on the back of a sharp slowdown in sales.
Read more
2023-10-09 (fiercepharma.com)
In cutting sales guidance, EuroAPI cites CDMO industry struggles and customers' inventory reductions
Flush with business during the COVID pandemic, the CDMO industry is struggling to adjust in the aftermath. | Flush with business during the COVID pandemic, the CDMO industry is struggling to adjust in the aftermath.
Read more
2023-01-31 (fiercepharma.com)
Euroapi resolves Budapest production snafu after taking 'considerable' financial blow: analyst
Sanofi’s drug ingredients spinoff Euroapi has made short work of its Hungarian manufacturing snafu—though not without incurring a sizable hit to its top line, one group of analysts contends. | Euroapi has made short work of its Hungarian manufacturing snafu.
Read more
2022-05-06 (reuters.com)
EuroAPI gains on market debut after spin-off from Sanofi
Shares in EuroAPI , the drug ingredients business spun off from Sanofi , rose on their Paris stock market debut on Friday, defying a wider market decline.
Read more
2021-01-13 (fiercepharma.com)
Meet EUROAPI: Sanofi christens to-be-spun-off drug ingredients business, taps CEO
Sanofi has tied a name—and a new chief executive—to the European drug ingredients business it plans to spin off next year. | Sanofi has tied a name—and a new chief executive—to the European drug ingredients business it plans to spin off next year.
Read more
(endpts.com)
EuroAPI halts production at Italian site as quality control issues due to 'potential' misconduct come to light
EuroAPI is pausing all production at its site in Brindisi, Italy, causing Sanofi's API spinoff to delay its 2024 guidance until the second ...
Read more